COVID-19 Impact on Solid Organ Transplant Recipients

Solid organ transplant recipients have been identified as a vulnerable population during the COVID-19 pandemic owing to long-term immunosuppression and frequent comorbidities. Infection in these individuals often presents with atypical immune responses, characterised by delayed viral clearance and blunted antibody production. Clinical manifestations range from mild upper respiratory symptoms to severe pneumonia, acute kidney injury and multi-organ dysfunction. Outcomes are influenced by factors such as type of transplanted organ, time since transplantation, baseline immunosuppressive regimen and presence of comorbid conditions. Globally, transplantation programmes experienced disruptions, leading to reduced access for waitlisted patients and potential loss of life-years. Despite these challenges, early antiviral therapy and careful modulation of immunosuppression have improved short-term prognosis. Long-term follow-up indicates that, while some recipients recover without graft impairment, others sustain persistent organ dysfunction and require intensified monitoring.

Research from Nature Portfolio

Recent multiomic profiling has revealed that transplant recipients exhibit higher nasal SARS-CoV-2 viral load and impaired clearance compared with non-transplant controls, alongside reduced anti-spike IgG titres. Cellular analyses showed diminished plasmablast and transitional B-cell populations, increased senescent T cells and upregulated innate immune signalling pathways. Paradoxically, severe cases in this group display a less robust induction of proinflammatory chemokines, suggesting unique dysregulation of antiviral defences. A systematic meta-analysis of mortality risk factors in kidney transplant recipients identified older age, receipt of a deceased-donor organ, diabetes, cardiovascular disease and active cancer as significant predictors of fatal outcome. Presentation with dyspnoea or pneumonia conferred high mortality risk, whereas gastrointestinal symptoms were linked to lower risk. Elevated inflammatory markers, including C-reactive protein and interleukin-6, and occurrence of acute kidney injury were also associated with increased death rates. These findings emphasise the need for personalised risk stratification and targeted interventions in transplant cohorts.

COVID-19 Impact on Solid Organ Transplant Recipients publication trend

The graph below shows the total number of articles in covid-19 impact on solid organ transplant recipients across all publications each year (not limited to Nature Index journals).

Technical terms

Immunosuppression: Pharmacological reduction of immune activity to prevent graft rejection.

Plasmablast: A short-lived, antibody-secreting B-cell precursor arising early during humoral responses.

Innate immune signalling pathways: Early, non-specific defence mechanisms mediated by pattern-recognition receptors.

Proinflammatory chemokines: Small cytokines that attract immune cells to sites of infection or inflammation.

Acute kidney injury (AKI): A sudden decline in renal function often seen in severe COVID-19 cases, associated with worse outcomes.

References

1. Host-microbe multiomic profiling identifies distinct COVID-19 immune dysregulation in solid organ transplant recipients. Nature Communications (2025).
2. Clinical features and outcomes in kidney transplant recipients with COVID-19 pneumonia: a single center retrospective cohort study. Frontiers in Cellular and Infection Microbiology (2024).
3. Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study. The Lancet Gastroenterology & Hepatology (2020).
4. COVID-19 pandemic and worldwide organ transplantation: a population-based study. The Lancet Public Health (2021).